Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 12/20 | 0.59 |
| ▸ | CCNH | P51946 | 12/20 | 0.59 |
| ▸ | MNAT1 | P51948 | 10/20 | 0.59 |
| ▸ | CCNK | O75909 | 14/20 | 0.55 |
| ▸ | CDK12 | Q9NYV4 | 14/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 13/20 | 0.55 |
| ▸ | CDK9 | P50750 | 13/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.55 |
| ▸ | CDK2 | P24941 | 12/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29083547 | 0.85 | MAPK3 (0.46) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL29083562 | 0.85 | MAPK3 (0.46) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL30439287 | 0.82 | CCNK (0.65) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL25596320 | 0.81 | CCNK (0.66) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL24583253 | 0.81 | CDK7 (0.43) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL16664896 | 0.78 | CCNT1 (0.74) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL30440015 | 0.78 | CCNT1 (0.74) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL29394684 | 0.78 | CCNT1 (0.74) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL30886754 | 0.78 | CCNT1 (0.74) | CDK7CCNHMNAT1CCNKCDK12 | |
| SCHEMBL16655161 | 0.78 | CCNT1 (0.74) | CDK7CCNHMNAT1CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540149-B2 | Aromatic heterocyclic compound, pharmaceutical composition, and use thereof | RECURSION PHARMACEUTICALS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20240132489-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | EXSCIENTIA AI LIMITED (GB) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132489-A1 | AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | CDK7, CDK17, CDK8 | CDK7 1/4885CCNH 51/4885MNAT1 212/4885 |
| US-12540149-B2 | Aromatic heterocyclic compound, pharmaceutical composition, and use thereof | CDK7, CDK17, CDK1 | CDK7 1/4885CCNH 63/4885MNAT1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.